Skip to main content

Peer Review reports

From: The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

Original Submission
17 Mar 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
15 Apr 2021 Reviewed Reviewer Report
20 Apr 2021 Reviewed Reviewer Report - Luciano Mutti
29 May 2021 Author responded Author comments - Farbod Shojaei
Resubmission - Version 3
29 May 2021 Submitted Manuscript version 3
1 Jun 2021 Author responded Author comments - Farbod Shojaei
Resubmission - Version 4
1 Jun 2021 Submitted Manuscript version 4
1 Jun 2021 Author responded Author comments - Farbod Shojaei
Resubmission - Version 5
1 Jun 2021 Submitted Manuscript version 5
2 Jun 2021 Author responded Author comments - Farbod Shojaei
Resubmission - Version 6
2 Jun 2021 Submitted Manuscript version 6
4 Jun 2021 Reviewed Reviewer Report - Luciano Mutti
17 Jun 2021 Reviewed Reviewer Report
9 Jul 2021 Author responded Author comments - Farbod Shojaei
Resubmission - Version 7
9 Jul 2021 Submitted Manuscript version 7
Publishing
16 Aug 2021 Editorially accepted
30 Aug 2021 Article published 10.1186/s12885-021-08702-x

You can find further information about peer review here.

Back to article page